Angiotensin II type 1 receptor-mediated peroxide production in human macrophages

Hypertension

Volumn 33, Issue 1 II, 1999, Pages 335-339

  Yanagitani, Yoshihiro ^b   Rakugi, Hiromi ^b   Okamura, Atsunori ^b   Moriguchi, Koichi ^b   Takiuchi, Shin ^b   Ohishi, Mitsuru ^b   Suzuki, Keiichiro ^b   Higaki, Jitsuo ^a   Ogihara, Toshio ^b  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b NONE

Author keywords

Angiotensin II; Atherosclerosis; Macrophages; Peroxide; Receptor antagonists

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; PEROXIDE;

ARTICLE; CYTOFLUOROMETRY; DRUG EFFECT; DRUG RECEPTOR BINDING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MACROPHAGE ACTIVATION; MONOCYTE; OXIDATIVE STRESS; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TISSUE REPAIR;

EID: 0032924040     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.hyp.33.1.335     Document Type: Article

References (38)

1. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial: the SAVE Investigators. N Engl J Med. 1992;327:669-677.
2. Ohishi M, Ueda M, Rakugi H, Naruko T, Kojima A, Okamura A, Higaki J, Ogihara T. Enhanced expression of angiotensin-converting enzyme is associated with progression of coronary atherosclerosis in humans. J Hypertens. 1997;15:1295-1302.
3. Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation. 1996;94:2756-2767.
4. Ohishi M, Ueda M, Rakugi H, Okamura A, Naruko T, Becker AE, Hiwada K, Kamitani A, Kamide K, Higaki J, Ogihara T. Upregulation of angiotensin-converting enzyme during the healing process after injury at the site of percutaneous transluminal coronary angioplasty in humans. Circulation. 1997;96:3328-3337.
5. Potter DD, Sobey CG, Tompkins PK, Rossen JD, Heistad DD. Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation. 1998;98:800-807.
6. Hanson SR, Powell JS, Dodson T, Lumsden A, Kelly AB, Anderson JS, Clowes AW, Harker LA. Effects of angiotensin converting enzyme inhibition with cilazapril on intimai hyperplasia in injured arteries and vascular grafts in the baboon. Hypertension. 1991;18(suppl II):II-70-II-76.
7. MERCATOR-Study-Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous trans-luminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Circulation. 1992;86:100-110.
8. Powell JS, Clozel JP, Muller RK, Kuhn H, Hefti F, Hosang M, Baumgartner HR. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science. 1989;245: 186-188.
9. Chobanian AV, Haudenschild CC, Nickerson C, Hope S. Trandolapril inhibits atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 1992;20:473-477.
10. Fennessy PA, Campbell JH, Campbell GR. Perindopril inhibits both the development of atherosclerosis in the cholesterol-fed rabbit and lipoprotein binding to smooth muscle cells in culture. Atherosclerosis. 1994;106:29-41.
11. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol. 1990;15:S65-S72.
12. Keidar S, Attias J, Smith J, Breslow JL, Hayek T. The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun. 1997;236:622-625.
13. Okamura A, Rakugi H, Ohishi M, Yanagitani Y, Moriguchi K, Higaki J, Ogihara T. Relationship between renin angiotensin system and the differentiation of monocytes to macrophages. J Hypertens. 1998;16(suppl 2):S3. Abstract.
14. Iwai N, Inagami T, Ohmichi N, Kinoshita M. Renin is expressed in rat macrophage/monocyte cells. Hypertension. 1996;27:399-403.
15. Scheidegger KJ, Butler S, Witztum JL. Angiotensin II increases macrophage-mediated modification of low density lipoprotein via a lipoxygenase-dependent pathway. J Biol Chem. 1997;272:21609-21615.
16. Thomas DW, Hoffman MD. Identification of macrophage receptors for angiotensin: a potential role in antigen uptake for T lymphocyte responses? J Immunol. 1984;132:2807-2812.
17. Keidar S, Kaplan M, Shapira C, Brook JG, Aviram M. Low density lipoprotein isolated from patients with essential hypertension exhibits increased propensity for oxidation and enhanced uptake by macrophages: a possible role for angiotensin II. Atherosclerosis. 1994;107:71-84.
18. Keidar S, Kaplan M, Hoffman A, Aviram M. Angiotensin II stimulates macrophage-medialed oxidation of low density lipoproteins. Atherosclerosis. 1995;115:201-215.
19. Rice Evans C, Leake D, Bruckdorfer KR, Diplock AT. Practical approaches to low density lipoprotein oxidation: whys, wherefores and pitfalls. Free Radic Res. 1996;25:285-311.
20. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro: implications for atherosclerotic plaque stability. J Clin Invest. 1996;98:2572-2579.
21. 2 for vascular smooth muscle cells is mediated by an increase of the affinity of basic fibroblast growth factor for its receptor. FEBS Lett. 1996;395:43-47.
22. Li PF, Dietz R, von Harsdorf R. Reactive oxygen species induce apoptosis of vascular smooth muscle cell. FEBS Lett. 1997;404:249-252.
23. Bass DA, Parce JW, Dechatelet LR, Szejda P, Seeds MC, Thomas M. Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation. J Immunol. 1983;130: 1910-1917.
24. Rao KM, Padmanabhan J, Kilby DL, Cohen HJ, Currie MS, Weinberg JB. Flow cytometric analysis of nitric oxide production in human neutrophils using dichlorofluorescein diacetate in the presence of a calmodulin inhibitor. J Leukoc Biol. 1992;51:496-500.
25. Nussberger J, Brunner DB, Waeber B, Brunner HR. Measurement of low angiotensin concentrations after ethanol and Dowex extraction procedures. J Lab Clin Med. 1984;103:304-312.
26. Suzuki YJ, Forman HJ, Sevanian A. Oxidants as stimulators of signal transduction. Free Radic Biol Med. 1997;22:269-285.
27. Nose K, Ohba M. Functional activation of the egr-1 (early growth response-1) gene by hydrogen peroxide. Biochem J. 1996;316:381-383.
28. Yla Herttuala S, Rosenfeld ME, Parthasarathy S, Sigal E, Sarkioja T, Witztum JL, Steinberg D. Gene expression in macrophage-rich human atherosclerotic lesions. 15-lipoxygenase and acetyl low density lipoprotein receptor messenger RNA colocalize with oxidation specific lipid-protein adducts. J Clin Invest. 1991;87:1146-1152.
29. Keidar S, Kaplan M, Aviram M. Angiotensin II-modified LDL is taken up by macrophages via the scavenger receptor, leading to cellular cholesterol accumulation. Arterioscler Thromb Vasc Biol. 1996;16:97-105.
30. Costerousse O, Allegrini J, Lopez M, Alhenc Gelas F. Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes. Biochem J. 1993;290:33-40.
31. Daemen MJ, Urata H. Healing human myocardial infarction associated with increased chymase immunoreactivity. Heart Vessels. 1997; 12(suppl):113-115.
32. Wintroub BU, Klickstein LB, Dzau VJ, Watt KW. Granulocyte-angiotensin system: identification of angiotensinogen as the plasma protein substrate of leukocyte cathepsin G. Biochemistry. 1984;23:227-232.
33. Owen CA, Campbell EJ. Angiotensin II generation at the cell surface of activated neutrophils: novel cathepsin G-mediated catalytic activity that is resistant to inhibition. J Immunol. 1998;160:1436-1443.
34. Kinscherf R, Claus R, Wagner M, Gehrke C, Kamencic H, Hou D, Nauen O, Schmiedt W, Kovacs G, Pill J, Metz J, Deigner HP. Apoptosis caused by oxidized LDL is manganese superoxide dismutase and p53 dependent. FASEB J. 1998;12:461-467.
35. Luoma JS, Stralin P, Marklund SL, Hiltunen TP, Sarkioja T, Yla Herttuala S. Expression of extracellular SOD and iNOS in macrophages and smooth muscle cells in human and rabbit atherosclerotic lesions: colocalization with epitopes characteristic of oxidized LDL and peroxynitrite-modified proteins. Arterioscler Thromb Vasc Biol. 1998;18:157-167.
36. Daugherty A, Dunn JL, Raten DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest. 1994;94:437-444.
37. Dzau VJ. Local expression and pathophysiological role of renin-angiotensin in the blood vessels and heart. Basic Res Cardiol. 1993;1:1-14.
38. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Ishimura Y, Chatani F, Iwao H. Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-beta 1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats. J Pharmacol Exp Ther. 1995;273:509-515.